Statin mediated protection of the ischemic myocardium (Q36142655)

12 August 2017

1 reference

title

Statin mediated protection of the ischemic myocardium (English)

1 reference

12 August 2017

Douglas G Wright

1

1 reference

12 August 2017

David J Lefer

series ordinal

2

1 reference

12 August 2017

publication date

23 March 2005

1 reference

12 August 2017

published in

Vascular Pharmacology

1 reference

12 August 2017

volume

42

1 reference

12 August 2017

issue

5-6

1 reference

12 August 2017

page(s)

265-270

1 reference

An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Early and Sustained Survival Benefit Associated With Statin Therapy at the Time of Percutaneous Coronary Intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Cellular survival: a play in three Akts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Inhibition of endothelial-derived nitric oxide promotes P-selectin expression and actions in the rat microcirculation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Role of nitric oxide in the control of mitochondrial function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Withdrawal of statins increases event rates in patients with acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Endogenous nitric oxide and myocardial adaptation to ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Effect of atorvastatin on the expression of CD40 ligand and P-selectin on platelets in patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Tyrosine 1101 of Tie2 is the major site of association of p85 and is required for activation of phosphatidylinositol 3-kinase and Akt

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Mechanisms of plaque stabilization with statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Statin therapy is associated with lower mortality among patients with severe heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Rapid regulation of platelet activation in vivo by nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Interstitial Collagenase (MMP-1) Expression in Human Carotid Atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Reduction of myocardial infarct size by fluvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Statins have biphasic effects on angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

Hmg-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.02.006

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VPH.2005.02.006

1 reference

12 August 2017

1 reference